Inventor · disambiguated record
Manuela Mally
Also filed as: MALLY MANUELA
14 granted patents·9 pending applications·73 citations·filing 2015–2025
90Inventor score
Files withGLAXOSMITHKLINE BIOLOGICALS SA7LIMMATECH BIOLOGICS AG7JANSSEN PHARMACEUTICALS INC6GLYCOERA AG2GLYCOVAXYN AG1
Top patents by PatentIndex Score
23 records- 0196US10940192B2Polysaccharide and uses thereofGLAXOSMITHKLINE BIOLOGICALS SA·Filed 2019·Granted Mar 9, 2021·11 cites·20 claims
- 0294US9700612B2Polysaccharide and uses thereofGLYCOVAXYN AG·Filed 2015·Granted Jul 11, 2017·27 cites·20 claims
- 0393US11738076B2Polysaccharide and uses thereofGLAXOSMITHKLINE BIOLOGICALS SA·Filed 2021·Granted Aug 29, 2023·2 cites·22 claims
- 0493US10583185B2Methods and compositions for immune protection against extra-intestinal pathogenic E. coliGLAXOSMITHKLINE BIOLOGICALS SA·Filed 2016·Granted Mar 10, 2020·12 cites·20 claims
- 0593US10441647B2Polysaccharide and uses thereofGLAXOSMITHKLINE BIOLOGICALS SA·Filed 2017·Granted Oct 15, 2019·13 cites·20 claims
- 0692US11446370B2Bioconjugates of E. coli o-antigen polysaccharides, methods of production thereof, and methods of use thereofJANSSEN PHARMACEUTICALS INC·Filed 2020·Granted Sep 20, 2022·6 cites·42 claims
- 0785US12214029B2Polysaccharide and uses thereofGLAXOSMITHKLINE BIOLOGICALS SA·Filed 2023·Granted Feb 4, 2025·0 cites·20 claims
- 0885US11931405B2Bioconjugates of E. coli O-antigen polysaccharides, methods of production thereof, and methods of use thereofJANSSEN PHARMACEUTICALS INC·Filed 2022·Granted Mar 19, 2024·1 cites·22 claims
- 0977US12076385B2Methods and compositions for immune protection against extra-intestinal pathogenic E. coliGLAXOSMITHKLINE BIOLOGICALS SA·Filed 2022·Granted Sep 3, 2024·0 cites·22 claims
- 1076US12233121B2Methods of producing bioconjugates of E. coli O-antigen polysaccharides, compositions thereof, and methods of use thereofJANSSEN PHARMACEUTICALS INC·Filed 2022·Granted Feb 25, 2025·0 cites·8 claims
- 1172US2024316172A1Bioconjugates of e. coli o-antigen polysaccharides, methods of production thereof, and methods of use thereofJANSSEN PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 1270US11236136B2Methods of producing glycosylated proteinsLIMMATECH BIOLOGICS AG·Filed 2016·Granted Feb 1, 2022·1 cites·13 claims
- 1370US2024287568A1Engineered and Fully-Functional Customized GlycoproteinsLIMMATECH BIOLOGICS AG·Filed 2024·Application pending·0 cites
- 1466US2025222093A1Methods of producing bioconjugates of e. coli o-antigen polysaccharides, compositions thereof, and methods of use thereofJANSSEN PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 1565US11484582B2Methods and compositions for immune protection against extra-intestinal pathogenic E. coliGLAXOSMITHKLINE BIOLOGICALS SA·Filed 2020·Granted Nov 1, 2022·0 cites·20 claims
- 1664US11491220B2Methods of producing bioconjugates of E. coli o-antigen polysaccharides, compositions thereof, and methods of use thereofJANSSEN PHARMACEUTICALS INC·Filed 2020·Granted Nov 8, 2022·0 cites·6 claims
- 1759US2022242919A1Methods of producing glycosylated proteinsLIMMATECH BIOLOGICS AG·Filed 2021·Application pending·0 cites
- 1856US11913051B2Engineered and fully-functional customized glycoproteinsLIMMATECH BIOLOGICS AG·Filed 2018·Granted Feb 27, 2024·0 cites·49 claims
- 1956US2025281626A1Mannose 3 glycan-mediated protein degradationGLYCOERA AG·Filed 2022·Application pending·0 cites
- 2056US2025282886A1Glycan-mediated protein degradationGLYCOERA AG·Filed 2022·Application pending·0 cites
- 2151US2024067714A1Fab sialylation of antibodiesLIMMATECH BIOLOGICS AG·Filed 2021·Application pending·0 cites
- 2250US2023287327A1Glycoengineering using leishmania cellsLIMMATECH BIOLOGICS AG·Filed 2021·Application pending·0 cites
- 2342US2023048847A1Engineered leishmania cellsLIMMATECH BIOLOGICS AG·Filed 2021·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Manuela Mally files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →